Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?

Bibliography

• FAVA M, RUSH AJ, THASE ME et al.: 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry (2005) 7(3):106-113.
   PubMedGoogle Scholar
• Practice guideline for the treatment of patients with major depressive disorder (revisions). Am. J. Psychiatry (2000) 157(Suppl. 4):24.
   Google Scholar
• MEHTA NB: The chemistry of bupropion. J. Clin. Psychiatry (1983) 44(Sec. 2):56-59.
   PubMedGoogle Scholar
• STAHL S, PRADKO JF, HAIGHT BK: A review of the neuropharmacology of bupropion SR, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion J. Clin. Psychiatry (2004) 6:159-166.
   PubMedGoogle Scholar
• LEARNED-COUGHLIN SM, BERGSTROM M, SAVITCHEVA I et al.: In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry (2003) 54:800-805.
   PubMed Web of Science ®Google Scholar
• SZABÓ Z, ÀRGYELÁN M, KANYÓ B et al.: The effect of bupropion on the activity of dopamine transporter in depression – preliminary results. Eur. Neuropsychopharmacol. (2003) 13(Suppl. 4):S210 Abstr. P.1.085.
   Google Scholar
• MEYER JH, GOULDING VS, WILSON AA et al.: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (2002) 163:102-105.
   PubMed Web of Science ®Google Scholar
• RICHELSON E: Synaptic effects of antidepressants. J. Clin. Psychopharmacol. (1996) 16(Suppl. 2):7S-9S.
   Google Scholar
• STAHL SM: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J. Clin. Psychiatry (1998) 59(Supp 18):23-29.
   PubMedGoogle Scholar
• Wellbutrin (bupropion) tablets, Wellbutrin SR (bupropion) and Wellbutrin XL (bupropion). Physician’s Desk Reference. Thomson PDR, Montvale, NJ (2005):1655-1659, 1659-1663, 1663-1668.
   Google Scholar
• JEFFERSON JW, PRADKO JF, MUIR KT: Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. (2005) 27:1685-1595.
   PubMed Web of Science ®Google Scholar
• FINDLAY JWA, VANWYCK FLEET J, SMITH PG et al.: Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur. J. Clin. Pharmacol. (1981) 21:127-135.
   PubMed Web of Science ®Google Scholar
• SCHROEDER DH: Metabolism and kinetics of bupropion. J. Clin. Psychiatry (1983) 44(5 Sec 2):79-81.
   PubMed Web of Science ®Google Scholar
• HESSE LM, VENKATAKRISHNAN K, COURT MG et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. (2000) 28(10):1176-1183.
   PubMed Web of Science ®Google Scholar
• DAVIS WB, PEREL JM, RUDOLPH GR et al.: Steady-state pharmacokinetics of bupropion SR in juvenile patients. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44:349-357.
   PubMedGoogle Scholar
• SWEET RA, POLLOCK BG, KIRSHNER M, REYNOLDS CF et al.: Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J. Clin. Pharmacol. (1995) 35:876-884.
   PubMed Web of Science ®Google Scholar
• STEWART JJ, BERKEL HJ, PARISH RC et al.: Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J. Clin. Pharmacol. (2001) 41:770-778.
   PubMed Web of Science ®Google Scholar
• HSYU PH, SINGH A, GIARGIARI TD, DUNN JA, ASCHER J, JOHNSTON JA: Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol. (1997) 37:737-743.
   PubMed Web of Science ®Google Scholar
• WORRALL SPR, ALMOND MK, DHILLON S: Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. Nephron Clin. Pract. (2004) 97:c93-c89.
   Google Scholar
• DEVANE CL, LAIZURE SC, STEWART JT et al.: Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J. Clin. Psychopharmacol. (1990) 10:328-332.
   PubMed Web of Science ®Google Scholar
• LINEBERRY CG, JOHNSTON JA, RAYMOND RN et al.: A fixed-dose efficacy study of bupropion and placebo in depressed outpatients. J. Clin. Psychiatry (1990) 51:194-199.
   PubMed Web of Science ®Google Scholar
• FABRE LF, BRODIE HK, GARVER D, ZUNG WK: A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J. Clin. Psychiatry (1983) 44(Sec 2):88-94.
   PubMed Web of Science ®Google Scholar
• MENDELS J, AMIN MH, CHOUINARD G et al.: A comparative study of bupropion and amitriptyline in depressed outpatients. J. Clin. Psychiatry (1983) 44(Sec 2):118-120
   PubMed Web of Science ®Google Scholar
• MASCO HL, KIEV A, WENGER T et al.: Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr. Ther. Res. (1994) 55:851-863.
   Web of Science ®Google Scholar
• FEIGHNER J, HENDRICKSON G, MILLER L, STERN W: Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J. Clin. Psychopharmacol. (1986) 6:27-32.
   PubMed Web of Science ®Google Scholar
• BRANCONNIER RJ, COLE JO, GHAZVINIAN S, SPERA KF, OXENFRUG GF, BASS JL: Clinical pharmacology of bupropion and imipramine in elderly depressives. J. Clin. Psychiatry (1983) 44(Sec 2):130-133.
   PubMed Web of Science ®Google Scholar
• WEISLER RH, JOHNSTON JA, LINEBERRY CG, SAMARA B, BRANCONNIER RJ, BILLOW AA: Comparison of bupropion and trazodone for the treatment of major depression. J. Clin. Psychopharmacol. (1994) 14:170-179.
   PubMed Web of Science ®Google Scholar
• FEIGHNER JP, GARDNER EA, JOHNSTON JA et al.: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J. Clin. Psychiatry (1991) 52:329-335.
   PubMed Web of Science ®Google Scholar
• COLEMAN CC, CUNNINGHAM LA, FOSTER VJ et al.: Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained-release and sertraline treatment. Ann. Clin. Psychiatry (1999) 11:205-215.
   PubMedGoogle Scholar
• CROFT H, SETTLE E, HOUSER T, BATEY SB, DONAHUE RM, ASCHER JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin. Ther. (1999) 21:643-658.
   PubMed Web of Science ®Google Scholar
• KAVOUSSI RJ, SEAGRAVE RT, HUGHES AR, ASCHER JA, JOHNSTON JA: Double-blind comparison of bupropion SR and sertraline in depressed outpatients. J. Clin. Psychiatry (1997) 58:532-537.
   PubMed Web of Science ®Google Scholar
• COLEMAN CC, KING BR, BOLDEN-WATSON C et al.: A placebo-controlled comparison on sexual functioning of bupropion SR and fluoxetine. Clin. Ther. (2001) 23:1040-1058.
   PubMed Web of Science ®Google Scholar
• WEIHS KL, SETTLE EC, BATEY SR, HOUSER TL, DONAHUE R, ASCHER JA: Bupropion sustained-release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry (2000) 61:196-202.
   PubMed Web of Science ®Google Scholar
• THASE ME, HAIGHT BR, RICHARD N et al.: Depression remission rates following therapy with bupropion or selective serotonin reuptake inhibitors: a pooled analysis of original data from seven randomized controlled trials. J. Clin. Psychiatry (2005) 66:974-981.
   PubMed Web of Science ®Google Scholar
• WEIHS L, HOUSER T, BATEY S et al.: Continuation phase treatment with bupropion SR decreases risk for relapse of depression. Biol. Psychiatry (2002) 51:753-761.
   PubMed Web of Science ®Google Scholar
• CLAYTON AH, CROFT HA, HORRIGAN JP et al.: Bupropion extended-release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry (2006) 67:736-746.
   PubMed Web of Science ®Google Scholar
• THASE ME, CLAYTON AH, HEIGHT BR et al.: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J. Clin. Psychopharmacol. (2006) 26:482-488.
   PubMed Web of Science ®Google Scholar
• THASE ME, CLAYTON AH, CHRZANOWSKI W et al.: Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials. Poster presentation at the Association of European Psychiatrists Annual Meeting. Nice, France (4 – 8 March 2006).
   Google Scholar
• BIRRER RB, VEMURI SP: Depression and later life: a diagnostic and therapeutic challenge. Am. Fam. Physician (2004) 69:2375-2382.
   PubMed Web of Science ®Google Scholar
• ROUSSEAU R, WIGHTMAN D, HEWETT K et al.: Efficacy and safety of bupropion XL in elderly patients with major depressive disorder. Poster presentation at the 159th American Psychiatric Association Annual Meeting. Toronto, Canada (20 – 25 May 2006). NR-982.
   Google Scholar
• DILSAVER SC, QAMAR AB, DEL MEDICO VJ: The efficacy of bupropion in winter depression: results of an open trial. J. Clin. Psychiatry (1992) 53:252-255
   PubMed Web of Science ®Google Scholar
• MODELL JG, ROSENTHAL NE, HARRIETT AE et al.: Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol. Psychiatry (2005) 58:658-667.
   PubMed Web of Science ®Google Scholar
• JEFFERSON JW, RUSH AJ, NELSON JC et al.: Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry (2006) 67:865-873.
   PubMed Web of Science ®Google Scholar
• RUSH AJ, TRIVEDI MH, CARMODY TJ et al.: Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology (2002) 25:131-138.
   Google Scholar
• TRIVEDI MH, RUSH AK, CARMODY TJ et al.: Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J. Clin. Psychiatry (2001) 62:776-781.
   PubMedGoogle Scholar
• FERGUSON J, CUNNINGHAM L, MERIDITH C et al.: Bupropion in tricyclic nonresponders with unipolar major depressive disorder. Ann. Clin. Psychiatry (1994) 6:153-169
   PubMedGoogle Scholar
• STERN WC, HARTO-TRUAX N, BAUER N: Efficacy of bupropion in tricyclic-resistant or intolerant patients. J. Clin. Psychiatry (1983) 44(Sec. 2):148-152.
   PubMedGoogle Scholar
• FAVA M, PAPAKOSTAS GI, PETERSEN T et al.: Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann. Clin. Psychiatry (2003) 15(1):17-22.
   PubMedGoogle Scholar
• BODKIN JA, LASSER RA, WINES JD, GARDNER DM, BALDESSERINI R: Combining SSRIs and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry (1997) 58:137-145.
   PubMed Web of Science ®Google Scholar
• SPIER SA: Use of bupropion with SSRIs and venlafaxine. Depress. Anxiety (1998) 7:73-75.
   PubMedGoogle Scholar
• DEBATTISTA C, SOLVASON HB, POIRIER J, KENDRICK E, SCHATZBURG A: A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J. Clin. Psychopharmacol. (2003) 23:27-30.
   PubMed Web of Science ®Google Scholar
• LAM RW, HOSSIE H, SOLOMONS K, YATHAM L: Citalopram and bupropion-SR: Combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry (2004) 65:337-340.
   PubMed Web of Science ®Google Scholar
• RUSH AJ, TRIVEDI MH, WISNIEWSKI SR et al.: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New Engl. J. Med. (2006) 354:1231-1242.
   PubMed Web of Science ®Google Scholar
• TRIVEDI MH, FAVA M, WISNIEWSKI SR et al.: Medication augmentation after failure of SSRIs for depression. New Engl. J. Med. (2006) 354:1243-1252.
   PubMed Web of Science ®Google Scholar
• SHOPSIN B: Bupropion’s prophylactic efficacy in bipolar affective illness. J. Clin. Psychiatry (1983) 44(Sec 2):163-169.
   PubMedGoogle Scholar
• WRIGHT G, GALLOWAY L, KIM J, DALTON M, MILLER L, STERN W: Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J. Clin. Psychiatry (1985) 46:22-25.
   PubMedGoogle Scholar
• SACHS GS, LAFER B, STOLL AL et al.: A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry (1994) 55:391-393.
   PubMed Web of Science ®Google Scholar
• GUILLE C, DEMOPULOS C, SACHS G: Bupropion versus desipramine in the treatment of bipolar depression. Poster Presentation at the American Psychiatric Association. Toronto, Canada (28 – 29 May 1998).
   Google Scholar
• MCINTYRE RS, MANCINI DA, MCCANN S, SRINIVASAN J, SAGMAN D, KENNEDY SH: Topriamate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. (2002) 4:207-213.
   Google Scholar
• WENDER PH, REIMHERR FW: Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am. J. Psychiatry (1990) 147:1018-1020.
   PubMed Web of Science ®Google Scholar
• BARRICKMAN LL, PERRY PJ, ALLEN AJ et al.: Bupropion versus methylphenidate in the treatment of ADHD. J. Am. Acad. Child Adolesc. Psychiatry (1995) 35:649-657.
   Google Scholar
• CONNERS CK, CASAT CD, GUALTIERI CT et al.: Bupropion in attention deficit disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry (1996) 34:1314-1321.
   Google Scholar
• WILENS TE, SPENCER TJ, BIEDERMAN J et al.: A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry (2001) 158:282-288.
   PubMed Web of Science ®Google Scholar
• WILENS TE, HAIGHT BR, HORRIGAN JP et al.: Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol. Psychiatry (2005) 57:793-801.
   PubMed Web of Science ®Google Scholar
• FERRY L, JOHNSTON JA: Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and 5 years of postmarketing experience. Int. J. Clin. Pract. (2003) 57:224-230.
   PubMed Web of Science ®Google Scholar
• HURT RD, SACHS DP, GLOVER ED et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. (1997) 227:1195-1202.
   Google Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA et al. : A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. (1999) 340:685-691.
   PubMed Web of Science ®Google Scholar
• HAYS JT, HURT RD, RIGOTTI NA et al.: Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann. Intern. Med. (2000) 135:423-433.
   Google Scholar
• GARDNER EA: Effects of bupropion on weight in patients intolerant to previous antidepressants. Curr. Ther. Res. (1985) 35:188-199.
   Google Scholar
• HARTO-TRUAX N, STERN WC, MILLER LL, SATO TL, CATO AE: Effects of bupropion on body weight. J. Clin. Psychiatry (1983) 44(Sec 2):183-186.
   PubMedGoogle Scholar
• GADDE KM, PARKER CB, MANER LG et al.: Bupropion for weight loss: investigation of efficacy and tolerability in overweight and obese women. Obes. Res. (2001) 9:544-551.
   PubMedGoogle Scholar
• JAIN AK, KAPLAN RA, GADDE KM et al.: Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes. Res. (2002) 10:1049-1056.
   PubMedGoogle Scholar
• ANDERSON JW, GREENWAY FL, FUJIOKA K, GADDE KM, MCKINNEY J, O’NEIL PM: Bupropion SR enhances weight loss; a 48-week double-blind, placebo-controlled trial. Obes. Res. (2002) 10:633-641.
   PubMedGoogle Scholar
• SEGRAVES RT, CROFT H, KAVOUSSI R et al.: Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J. Sex Marital Ther. (2001) 27:303-316.
   PubMed Web of Science ®Google Scholar
• SEGRAVES RT, CLATYON A, CROFT H, WOLF A, WARNOCK J: Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol. (2004) 24:339-342.
   PubMed Web of Science ®Google Scholar
• MODELL JG, MAY RS, KATHOLI CR: Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J. Sex Marital Ther. (2000) 26:231-240.
   PubMed Web of Science ®Google Scholar
• SETTLE EC, STAHL SM, BATEY SR, JOHNSTON JA, ASCHER JA: Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin. Ther. (1999) 21:454-463.
   PubMed Web of Science ®Google Scholar
• DUNNER DL, ZISOOK S, BILLOW AA, BATEY SR, JOHNSTON JA, ASCHER JA: a prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry (1998) 59:366-373.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA: Antidepressants and seizures: emphasis on newer agents and clinical implications. Int. J. Clin. Pract. (2005) 59:1435-1440.
   PubMed Web of Science ®Google Scholar
• THASE ME, HAIGHT B, HUNT T et al.: Bupropion SR does not affect blood pressure of hypertensive patients. Poster presentation at the American Psychiatric Association. San Francisco, CA, USA (17 – 22 May, 2003).
   Google Scholar
• GARDNER EA, JOHNSTON JA: Bupropion – an antidepressant without sexual pathophysiological action. J. Clin. Psychopharmacol. (1985) 5:24-29.
   PubMed Web of Science ®Google Scholar
• CLAYTON AH, PRADKO JF, CROFT HA et al.: Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry (2002) 63:357-366.
   PubMed Web of Science ®Google Scholar
• CLAYTON AH, WARNOCK JK, KORNSTEIN SG, PINKERTON R, SHELDON-KELLER A, MCGARVEY EL: A placebo-controlled trial of bupropion SR as an antidote for SSRI induced sexual dysfunction. J. Clin. Psychiatry (2004) 65:62-67.
   PubMed Web of Science ®Google Scholar
• CLAYTON AH, MCGARVEY EL, ABOUESH AI, PINKERTON RC: Substitution of an SSRI with bupropion SR following SSRI-induced sexual dysfunction. J. Clin. Psychiatry (2001) 62:185-190.
   PubMed Web of Science ®Google Scholar
• SEMENCHUK MR, SHERMAN S, DAVIS B: Double-blind, randomized trial of bupropion SR for the treatment of neruopathic pain. Neurology (2001) 57:1583-1588.
   PubMedGoogle Scholar
• MCLAUGHLIN TP, HOGUE SL, STANG P: Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am. J. Ther. In Press.
   Google Scholar